β-醇通过调节酶酶来缓解动脉样硬化
Shuntao Jiang1, Kui Gao2, Furong Zhang3
1Department of Cardiovascular Medicine, Affiliated Hospital of Zunyi Medical University, No. 149, Dalian Road, Huichuan District, Zunyi, 563000, Guizhou, China.
Heliyon
|August 21, 2024
概括
来自 Gegen (Puerariae Lobatae Radix) 的β-固醇通过抑制斑块形成和脂质沉积,有效地对抗动脉样硬化. 它通过激活酶和沉默PI3K/Akt/mTOR途径来起作用,提供了一个潜在的治疗策略.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
- 心血管研究研究心血管研究
背景情况:
- 动脉样硬化是一种慢性炎症性疾病,其特点是动脉中积聚斑块.
- Gegen (Puerariae Lobatae Radix) 是一种具有潜在心血管益处的传统中医药.
- 确定活性成分和机制对于治疗开发至关重要.
研究的目的:
- 为了确定负责抗动脉样硬化作用的 Gegen 主要活性成分.
- 阐明这种成分在预防和治疗动脉样硬化的作用机制.
主要方法:
- 生物信息学分析以预测活性化合物.
- 在体内研究评估斑块形成,血小板激活和脂质概况.
- 在体外实验中评估脂质沉积和血管光滑肌细胞 (VSMC) 行为的实验.
- 基因淘汰和通路抑制实验 (催化酶,PI3K/Akt/mTOR).
主要成果:
- 贝塔-固醇被确定为Gegen.的关键抗动脉样硬化成分.
- 在体内:β-降低了斑块形成,血小板激活,血清总胆固醇和甘油三.
- 在体外:β-固醇抑制了VSMC脂质沉积和表型转变.
- 催化酶倒置加剧了脂质沉积和VSMC变化,激活PI3K/Akt/mTOR通路.
- mTOR抑制逆转了催化酶淘汰的作用.
结论:
- 贝塔-固醇通过抑制VSMC脂质沉积和表型转变来缓解动脉样硬化.
- 该机制涉及激活催化酶和抑制PI3K/Akt/mTOR信号通路.
- 贝塔-固醇是动脉样硬化的有前途的治疗药物.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
604
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
604
01:17Antihypertensive Drugs: Action of β1 Blockers
356
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
356
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
421
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
421
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
541
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
541
01:28Antihypertensive Drugs: Types of β-Blockers
613
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
613
01:38Inflammation
53.2K
Overview
53.2K